Published in J Proteome Res on May 07, 2010
A large-scale method to measure absolute protein phosphorylation stoichiometries. Nat Methods (2011) 1.87
Advancing the sensitivity of selected reaction monitoring-based targeted quantitative proteomics. Proteomics (2012) 1.30
Quantification of beta-catenin signaling components in colon cancer cell lines, tissue sections, and microdissected tumor cells using reaction monitoring mass spectrometry. J Proteome Res (2010) 1.20
Mass spectrometry mapping of epidermal growth factor receptor phosphorylation related to oncogenic mutations and tyrosine kinase inhibitor sensitivity. J Proteome Res (2010) 1.10
Large-Scale Interlaboratory Study to Develop, Analytically Validate and Apply Highly Multiplexed, Quantitative Peptide Assays to Measure Cancer-Relevant Proteins in Plasma. Mol Cell Proteomics (2015) 1.02
Identification and selected reaction monitoring (SRM) quantification of endocytosis factors associated with Numb. Mol Cell Proteomics (2012) 0.91
Using quantitative proteomic analysis to understand genotype specific intrinsic drug resistance in melanoma. Oncotarget (2011) 0.84
Novel mass spectrometric method for phosphorylation quantification using cerium oxide nanoparticles and tandem mass tags. Anal Chem (2012) 0.79
Tyrosine phosphorylation of the Lyn Src homology 2 (SH2) domain modulates its binding affinity and specificity. Mol Cell Proteomics (2015) 0.79
Evaluation of direct infusion-multiple reaction monitoring mass spectrometry for quantification of heat shock proteins. Anal Chem (2012) 0.78
A general strategy for studying multisite protein phosphorylation using label-free selected reaction monitoring mass spectrometry. Anal Biochem (2011) 0.78
Current technologies to identify protein kinase substrates in high throughput. Front Biol (Beijing) (2013) 0.78
Evaluating kinase ATP uptake and tyrosine phosphorylation using multiplexed quantification of chemically labeled and post-translationally modified peptides. Methods (2015) 0.77
Evaluation of protein quantification using standard peptides containing single conservative amino acid replacements. J Mass Spectrom (2012) 0.77
Use of quantitative mass spectrometric analysis to elucidate the mechanisms of phospho-priming and auto-activation of the checkpoint kinase Rad53 in vivo. Mol Cell Proteomics (2013) 0.76
Quantifying Kinase-Specific Phosphorylation Stoichiometry Using Stable Isotope Labeling In a Reverse In-Gel Kinase Assay. Anal Chem (2016) 0.75
Systematic identification of protein complexes in Saccharomyces cerevisiae by mass spectrometry. Nature (2002) 37.66
Initial genome sequencing and analysis of multiple myeloma. Nature (2011) 17.28
Large-scale mapping of human protein-protein interactions by mass spectrometry. Mol Syst Biol (2007) 8.16
A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood (2012) 5.11
Human Proteinpedia enables sharing of human protein data. Nat Biotechnol (2008) 4.21
Proteomic, functional, and domain-based analysis of in vivo 14-3-3 binding proteins involved in cytoskeletal regulation and cellular organization. Curr Biol (2004) 3.45
Insights into antifolate resistance from malarial DHFR-TS structures. Nat Struct Biol (2003) 3.20
Single-center experience of encapsulating peritoneal sclerosis in patients on peritoneal dialysis for end-stage renal failure. Kidney Int (2005) 2.29
Predictive adaptive responses to maternal high-fat diet prevent endothelial dysfunction but not hypertension in adult rat offspring. Circulation (2004) 2.28
Use of a computerized guideline for glucose regulation in the intensive care unit improved both guideline adherence and glucose regulation. J Am Med Inform Assoc (2004) 1.85
Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma. Blood (2010) 1.79
Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia. J Clin Oncol (2010) 1.77
Clinical Practice Guidelines and Recommendations on Peritoneal Dialysis Adequacy 2011. Perit Dial Int (2011) 1.76
Increased selectivity, analytical precision, and throughput in targeted proteomics. Mol Cell Proteomics (2010) 1.71
Computer-aided detection in the United Kingdom National Breast Screening Programme: prospective study. Radiology (2005) 1.63
A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma. Clin Cancer Res (2012) 1.60
Structural and biochemical studies of human proliferating cell nuclear antigen complexes provide a rationale for cyclin association and inhibitor design. Proc Natl Acad Sci U S A (2005) 1.57
Mechanism of Mos1 transposition: insights from structural analysis. EMBO J (2006) 1.48
An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma. Clin Lymphoma Myeloma Leuk (2012) 1.48
Inhibitors of Polo-like kinase reveal roles in spindle-pole maintenance. Nat Chem Biol (2006) 1.47
A strategy for modulation of enzymes in the ubiquitin system. Science (2013) 1.43
Global proteomic assessment of the classical protein-tyrosine phosphatome and "Redoxome". Cell (2011) 1.34
Selected reaction monitoring-mass spectrometric immunoassay responsive to parathyroid hormone and related variants. Clin Chem (2009) 1.28
Myxoma virus M11L prevents apoptosis through constitutive interaction with Bak. J Virol (2004) 1.27
Phase I-II trial of bortezomib plus oral cyclophosphamide and prednisone in relapsed and refractory multiple myeloma. J Clin Oncol (2008) 1.23
Preclinical studies of fibroblast growth factor receptor 3 as a therapeutic target in multiple myeloma. Br J Haematol (2004) 1.20
Automated 2D peptide separation on a 1D nano-LC-MS system. J Proteome Res (2009) 1.19
Thymidylate synthase expression and outcome of patients receiving pemetrexed for advanced nonsquamous non-small-cell lung cancer in a prospective blinded assessment phase II clinical trial. J Thorac Oncol (2013) 1.17
Simultaneous analysis of glycosylated and sialylated prostate-specific antigen revealing differential distribution of glycosylated prostate-specific antigen isoforms in prostate cancer tissues. Anal Chem (2010) 1.16
S-nitrosylation of AtSABP3 antagonizes the expression of plant immunity. J Biol Chem (2008) 1.16
Dietary soy isoflavone induced increases in antioxidant and eNOS gene expression lead to improved endothelial function and reduced blood pressure in vivo. FASEB J (2005) 1.14
A structure-based mutational analysis of cyclophilin 40 identifies key residues in the core tetratricopeptide repeat domain that mediate binding to Hsp90. J Biol Chem (2002) 1.13
Visuomotor priming by pictures of hand postures: perspective matters. Neuropsychologia (2003) 1.12
Octaheme tetrathionate reductase is a respiratory enzyme with novel heme ligation. Nat Struct Mol Biol (2004) 1.10
Second autologous stem cell transplantation as salvage therapy for multiple myeloma: impact on progression-free and overall survival. Biol Blood Marrow Transplant (2011) 1.10
Epidermal growth factor receptor variant III-induced glioma invasion is mediated through myristoylated alanine-rich protein kinase C substrate overexpression. Cancer Res (2009) 1.10
Quantitative phosphoproteomic analysis of the STAT3/IL-6/HIF1alpha signaling network: an initial study in GSC11 glioblastoma stem cells. J Proteome Res (2010) 1.09
B56 regulatory subunit of protein phosphatase 2A mediates valproic acid-induced p300 degradation. Mol Cell Biol (2005) 1.09
Effect of noncompetitive proteasome inhibition on bortezomib resistance. J Natl Cancer Inst (2010) 1.09
Effect of high-dose intravenous vitamin C on inflammation in cancer patients. J Transl Med (2012) 1.09
A small-molecule inhibitor of D-cyclin transactivation displays preclinical efficacy in myeloma and leukemia via phosphoinositide 3-kinase pathway. Blood (2010) 1.09
Cyproheptadine displays preclinical activity in myeloma and leukemia. Blood (2008) 1.08
Multi-intervention management of calciphylaxis: a report of 7 cases. Am J Kidney Dis (2011) 1.08
A pilot clinical study of continuous intravenous ascorbate in terminal cancer patients. P R Health Sci J (2005) 1.08
The human phosphotyrosine signaling network: evolution and hotspots of hijacking in cancer. Genome Res (2011) 1.07
Epidermal growth factor receptor phosphorylation sites Ser991 and Tyr998 are implicated in the regulation of receptor endocytosis and phosphorylations at Ser1039 and Thr1041. Mol Cell Proteomics (2009) 1.07
Quality control metrics for LC-MS feature detection tools demonstrated on Saccharomyces cerevisiae proteomic profiles. J Proteome Res (2006) 1.07
CHIR-258 is efficacious in a newly developed fibroblast growth factor receptor 3-expressing orthotopic multiple myeloma model in mice. Clin Cancer Res (2006) 1.06
Exploiting the mevalonate pathway to distinguish statin-sensitive multiple myeloma. Blood (2010) 1.05
Homologues of human macrophage migration inhibitory factor from a parasitic nematode. Gene cloning, protein activity, and crystal structure. J Biol Chem (2002) 1.04
A chemical biology screen identifies glucocorticoids that regulate c-maf expression by increasing its proteasomal degradation through up-regulation of ubiquitin. Blood (2007) 1.03
Immunohistochemistry accurately predicts FGFR3 aberrant expression and t(4;14) in multiple myeloma. Blood (2005) 1.03
Expression, purification and preliminary crystallographic studies of a single-point mutant of Mos1 mariner transposase. Acta Crystallogr D Biol Crystallogr (2004) 1.03
A systematic review of computer-assisted diagnosis in diagnostic cancer imaging. Eur J Radiol (2011) 1.02
Mass spectrometric discovery and selective reaction monitoring (SRM) of putative protein biomarker candidates in first trimester Trisomy 21 maternal serum. J Proteome Res (2010) 1.02
A mass spectrometry based method for distinguishing between symmetrically and asymmetrically dimethylated arginine residues. Rapid Commun Mass Spectrom (2004) 1.01
Selected Reaction Monitoring (SRM) Analysis of Epidermal Growth Factor Receptor (EGFR) in Formalin Fixed Tumor Tissue. Clin Proteomics (2012) 1.01
Phosphorylation of rat liver mitochondrial carnitine palmitoyltransferase-I: effect on the kinetic properties of the enzyme. J Biol Chem (2004) 1.01
Identification of a non-phosphorylated, cell permeable, small molecule ligand for the Stat3 SH2 domain. Bioorg Med Chem Lett (2011) 1.00
Overexpression of the myeloma-associated oncogene fibroblast growth factor receptor 3 confers dexamethasone resistance. Blood (2002) 0.99
Making decisions about mammography. BMJ (2005) 0.99
Antagonism of the Stat3-Stat3 protein dimer with salicylic acid based small molecules. ChemMedChem (2011) 0.99
Clinical outcomes in t(4;14) multiple myeloma: a chemotherapy-sensitive disease characterized by rapid relapse and alkylating agent resistance. J Clin Oncol (2005) 0.99
Soluble interleukin-13Ralpha2 decoy receptor inhibits Hodgkin's lymphoma growth in vitro and in vivo. Cancer Res (2004) 0.98
Structures of immunophilins and their ligand complexes. Curr Top Med Chem (2003) 0.98
Crystal structure of a thermostable lipase from Bacillus stearothermophilus P1. J Mol Biol (2002) 0.98
System-level analysis of neuroblastoma tumor-initiating cells implicates AURKB as a novel drug target for neuroblastoma. Clin Cancer Res (2010) 0.97
EDULISS: a small-molecule database with data-mining and pharmacophore searching capabilities. Nucleic Acids Res (2010) 0.96
Intravenous ascorbic acid: protocol for its application and use. P R Health Sci J (2003) 0.96
Discovery of a novel family of CDK inhibitors with the program LIDAEUS: structural basis for ligand-induced disordering of the activation loop. Structure (2003) 0.96
Multiple myeloma phosphotyrosine proteomic profile associated with FGFR3 expression, ligand activation, and drug inhibition. Proc Natl Acad Sci U S A (2009) 0.96
Oral ciclopirox olamine displays biological activity in a phase I study in patients with advanced hematologic malignancies. Am J Hematol (2014) 0.95
A targeted proteomic approach for the analysis of rat liver mitochondrial outer membrane proteins with extensive sequence coverage. Anal Biochem (2006) 0.95
Evaluation of absolute peptide quantitation strategies using selected reaction monitoring. Proteomics (2011) 0.95
Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for heavily pretreated relapsed or refractory multiple myeloma. Leuk Lymphoma (2013) 0.94
Molecular basis for Jagged-1/Serrate ligand recognition by the Notch receptor. J Biol Chem (2013) 0.92
The tricyclic antidepressant amitriptyline inhibits D-cyclin transactivation and induces myeloma cell apoptosis by inhibiting histone deacetylases: in vitro and in silico evidence. Mol Pharmacol (2011) 0.92
Discrimination of ischemic and hemorrhagic strokes using a multiplexed, mass spectrometry-based assay for serum apolipoproteins coupled to multi-marker ROC algorithm. Proteomics Clin Appl (2012) 0.91
Tandem immunoprecipitation of phosphotyrosine-mass spectrometry (TIPY-MS) indicates C19ORF19 becomes tyrosine-phosphorylated and associated with activated epidermal growth factor receptor. J Proteome Res (2008) 0.91
MIP-1alpha (CCL3) is a downstream target of FGFR3 and RAS-MAPK signaling in multiple myeloma. Blood (2006) 0.91
Weekly cyclophosphamide and alternate-day prednisone: an effective, convenient, and well-tolerated oral treatment for relapsed multiple myeloma after autologous stem cell transplantation. Mayo Clin Proc (2005) 0.91